Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amir T Fathi

Showing results (71-80 of 182) with videos related to

Pageof 19
Sort By:
Future Oncology (London, England)|July 19, 2022
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemiaVladimir Ivanov, Su-Peng Yeh, Jiri Mayer, et al.
Leukemia Research|April 10, 2025
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 studyMonzr M Al Malki, Mark D Minden, Elizabeth Shima Rich, et al.
Leukemia Research|October 7, 2018
Clustered incidence of adult acute promyelocytic leukemiaAndrew M Brunner, Peter Geon Kim, Hossein Sadrzadeh, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 12, 2020
Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal ProphylaxisJessie Signorelli, Matthew Lei, Jenna Lam, et al.
Leukemia & Lymphoma|September 13, 2012
CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosisAmir T Fathi, Frederic I Preffer, Hossein Sadrzadeh, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Blood|May 7, 2013
AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathwayYiyun Zhang, Jianfeng Wang, Justin Wheat, et al.
Blood Advances|March 20, 2024
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trialsPau Montesinos, Amir T Fathi, Stéphane de Botton, et al.
The Oncologist|May 31, 2022
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and ImmunotherapyValentina Nardi, Steven L McAfee, Paola Dal Cin, et al.
Haematologica|August 18, 2025
Strategies for identifying <i>NUP98</i> rearrangements in adult myeloid neoplasmsLisa D Yuen, Robert P Hasserjian, Amir T Fathi, et al.
Pageof 19

Showing results (71-80 of 182) with videos related to

Sort By:
Pageof 19
Future Oncology (London, England)|July 19, 2022
Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemiaVladimir Ivanov, Su-Peng Yeh, Jiri Mayer, et al.
Leukemia Research|April 10, 2025
Safety, tolerability, and pharmacokinetics of ASP1235 in relapsed or refractory acute myeloid leukemia: A phase 1 studyMonzr M Al Malki, Mark D Minden, Elizabeth Shima Rich, et al.
Leukemia Research|October 7, 2018
Clustered incidence of adult acute promyelocytic leukemiaAndrew M Brunner, Peter Geon Kim, Hossein Sadrzadeh, et al.
Clinical Lymphoma, Myeloma & Leukemia|September 12, 2020
Incidence of Invasive Fungal Infections in Acute Myeloid Leukemia Without Antifungal ProphylaxisJessie Signorelli, Matthew Lei, Jenna Lam, et al.
Leukemia & Lymphoma|September 13, 2012
CD30 expression in acute myeloid leukemia is associated with FLT3-internal tandem duplication mutation and leukocytosisAmir T Fathi, Frederic I Preffer, Hossein Sadrzadeh, et al.
JCO Precision Oncology|February 17, 2022
Combined Targeted Therapy for <i>BRAF</i>-Mutant, Treatment-Related Acute Myeloid LeukemiaSeth A Wander, Robert P Hasserjian, Kwadwo Oduro, et al.
Blood|May 7, 2013
AML1-ETO mediates hematopoietic self-renewal and leukemogenesis through a COX/β-catenin signaling pathwayYiyun Zhang, Jianfeng Wang, Justin Wheat, et al.
Blood Advances|March 20, 2024
Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trialsPau Montesinos, Amir T Fathi, Stéphane de Botton, et al.
The Oncologist|May 31, 2022
Chemotherapy Resistance in B-ALL with Cryptic NUP214-ABL1 Is Amenable to Kinase Inhibition and ImmunotherapyValentina Nardi, Steven L McAfee, Paola Dal Cin, et al.
Haematologica|August 18, 2025
Strategies for identifying <i>NUP98</i> rearrangements in adult myeloid neoplasmsLisa D Yuen, Robert P Hasserjian, Amir T Fathi, et al.
Pageof 19